Skip to Content

Lineage Cell Therapeutics Inc LCTX

Morningstar Rating
$1.04 +0.01 (0.97%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LCTX is trading within a range we consider fairly valued.
Price
$1.02
Fair Value
$2.75
Uncertainty
Extreme
1-Star Price
$57.25
5-Star Price
$3.89
Economic Moat
Vjlmp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LCTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.03
Day Range
$1.031.06
52-Week Range
$0.841.57
Bid/Ask
$1.07 / $1.08
Market Cap
$196.02 Mil
Volume/Avg
431,054 / 798,669

Key Statistics

Price/Earnings (Normalized)
Price/Sales
20.13
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
78

Comparables

Valuation

Metric
LCTX
BLUE
FDMT
Price/Earnings (Normalized)
Price/Book Value
2.650.493.60
Price/Sales
20.134.7946.21
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
LCTX
BLUE
FDMT
Quick Ratio
2.631.2417.60
Current Ratio
2.741.5518.07
Interest Coverage
Quick Ratio
LCTX
BLUE
FDMT

Profitability

Metric
LCTX
BLUE
FDMT
Return on Assets (Normalized)
−15.61%−12.29%−25.86%
Return on Equity (Normalized)
−25.16%−30.63%−28.60%
Return on Invested Capital (Normalized)
−26.52%−15.27%−30.22%
Return on Assets
LCTX
BLUE
FDMT
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVzr$550.2 Bil
VRTX
Vertex Pharmaceuticals IncLbhccw$111.1 Bil
REGN
Regeneron Pharmaceuticals IncHlqgd$107.7 Bil
MRNA
Moderna IncZqyw$36.9 Bil
ARGX
argenx SE ADRKcxl$24.2 Bil
BNTX
BioNTech SE ADRZsvql$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncHwfwz$19.9 Bil
BMRN
Biomarin Pharmaceutical IncLyyxby$17.2 Bil
RPRX
Royalty Pharma PLC Class ALhnvgg$13.9 Bil
INCY
Incyte CorpGnwzntm$13.6 Bil

Sponsor Center